retatrutide phase 3 trial Michael Weintraub, MD on X: "Looking forward to when #retatrutide's results will become available. There are are 4 planned TRIUMPH trials investigating retatrutide's efficacy in treating obesity and its Lilly's triple agonist achieves 16.8%

Thats exactly who should be getting this therapy. Targeting Alstrm Syndrome In Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alstrm Syndrome, a Rare Obesity Syndrome , published in JCEM in April, Thomas Scherer, MD, of the Medical University of Vienna, in Vienna, Austria, and team showed tirzepatides efficacy even in the particularly difficult-to-treat Alstrm syndrome (AS), a rare, genetic, multisystemic disorder, characterized by, among other conditions, diabetes with profound insulin resistance due to marked hyperphagia

BPC-157 shows promising potential for plantar fasciitis based on its demonstrated ability to accelerate tendon and ligament healing in research studies

Innovations like CRISPR have made the prospect of editing mutations out of DNA a tantalizing one, but as a therapeutic, the technology has a few drawbacks

Injections can be crucial for restoring adequate levels, promoting better health, and preventing the long-term consequences of deficiency